Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. MSFT
6. NVDA
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance

Gilead Sciences Announces Third Quarter 2020 Financial Results

October 28, 2020 4:01 PM EDT

Third Quarter 2020 Highlights: Year-Over-Year

- Product Sales increased 18% to $6.5 billion -

- Product Sales excluding Veklury increased 2% to $5.6 billion -

-  GAAP Diluted EPS of $0.29 -

-  Non-GAAP Diluted EPS increased 29% to $2.11 -

-  Acquisition of Immunomedics, Inc. -

Updated Full Year 2020 Guidance

-  Product Sales of $23 billion to $23.5 billion -

-... More